Lugano/Bern, September 7, 2018
On September 7, Cerbios was honored by the visit of the US Ambassador to Switzerland and Liechtenstein, Edward McMullen Jr.
Aim of the visit of the Ambassador was to meet Cerbios’ top management and shareholder in order to have a better view and understanding of Cerbios’ ongoing and future activities in the USA.
Cerbios is active in the USA since 1982 with an established leadership with its reduced folates products used in oncology. In the past years, activities have strongly increased as service provider and CDMO (Contract Development and Manufacturing Operation) for originators needing Cerbios’ expertise and know-how in handling and producing High Potency Active Ingredients (HPAIs) of the newest generation.
“Cerbios’ forecasted growth in the coming years means an increased presence in the USA” confirms Gabriel Haering, Cerbios’ CEO. “Establishing an affiliate company through acquisition or a joint venture is an option we are considering in order to better serve our partners locally. The support of the US Embassy in Bern has really been remarkable till now“.
“I was really positively surprised to discover not only Cerbios’ unique and innovative activities but also that a small canton like Ticino has an important Pharmaceutical Cluster heavily contributing to the canton’s GDP” says Ambassador McMullen. “It is our goal to support Cerbios and other Swiss companies in strengthening their activities in the United States“.
About Cerbios-Pharma SA
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of both chemical and biological APIs for its partners world-wide. Cerbios is a global leading supplier of a portfolio of Generic APIs primarily used for the treatment of Respiratory and Dermatological disorders as well as in Oncology. Exclusive, CDMO services are offered for the development and manufacturing of HPAIs as well as for Biological products including monoclonal antibodies, recombinant proteins, Antibody Drug Conjugates (ADCs) and pharma probiotics. Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
More information can be found at www.cerbios.ch
For more information please contact:
Chief Commercial Officer
Phone: +41 (0) 91 985 63 11
Fax: +41(0) 91 985 63 25